Literature DB >> 7597295

Use of polymerase chain reaction in the detection of clones in lymphoproliferative diseases of the skin.

G Staib1, W Sterry.   

Abstract

Early-stage mycosis fungoides shows similar clinical symptoms and histological and immunophenotypical features to several benign lymphoproliferative skin disorders. We analyzed T cell receptor gamma gene rearrangement by polymerase chain reaction in the search for monoclonal lymphoid subpopulations in skin infiltrates. Totally, 283 skin biopsies (paraffin-embedded and frozen material) from patients with different malignant and reactive skin diseases were investigated. Using primers for the T cell receptor gamma chain gene, monoclonality was detected in 59 out of 66 (89%) cases of pleomorphic cutaneous lymphoma, in 60 out of 78 (77%) patients with mycosis fungoides, in 11 out of 22 (50%) cases of parapsoriasis en plaques, in five out of 35 (14%) cases of pseudolymphoma, in six out of 15 (40%) patients with lymphomatoid papulosis, and in none out of 64 patients with inflammatory skin diseases. The results show that clonal T cell population can be detected in the majority of patients with cutaneous T cell lymphoma, but the findings have to be correlated with the histological and morphological features.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7597295     DOI: 10.1007/978-3-642-78771-3_18

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  2 in total

1.  Clonal T-cell receptor β-chain gene rearrangements in differential diagnosis of lymphomatoid papulosis from skin metastasis of nodal anaplastic large-cell lymphoma.

Authors:  Oleg E Akilov; Raju K Pillai; Lisa M Grandinetti; Jeffrey A Kant; Larisa Geskin
Journal:  Arch Dermatol       Date:  2011-08

2.  Monoclonal gamma-T-cell receptor rearrangement in vulvar lichen sclerosus and squamous cell carcinomas.

Authors:  Sigrid Regauer; Olaf Reich; Christine Beham-Schmid
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.